Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 NK cells and cancer: you can teach innate cells new tricks.

Literature DB >> 26694935

NK cells and cancer: you can teach innate cells new tricks.

Abstract

Natural killer (NK) cells are the prototype innate lymphoid cells endowed with potent cytolytic function that provide host defence against microbial infection and tumours. Here, we review evidence for the role of NK cells in immune surveillance against cancer and highlight new therapeutic approaches for targeting NK cells in the treatment of cancer.

Entities: Disease

Mesh：

Substances：

Year: 2016 PMID： 26694935 DOI： 10.1038/nrc.2015.5

Source DB: PubMed Journal: Nat Rev Cancer ISSN： 1474-175X Impact factor: 60.716

185 in total

1. Expansion of a unique CD57⁺NKG2Chi natural killer cell subset during acute human cytomegalovirus infection.

Authors: Sandra Lopez-Vergès; Jeffrey M Milush; Brian S Schwartz; Marcelo J Pando; Jessica Jarjoura; Vanessa A York; Jeffrey P Houchins; Steve Miller; Sang-Mo Kang; Phillip J Norris; Douglas F Nixon; Lewis L Lanier
Journal: Proc Natl Acad Sci U S A Date: 2011-08-08 Impact factor: 11.205

2. DAP12-based activating chimeric antigen receptor for NK cell tumor immunotherapy.

Authors: Katrin Töpfer; Marc Cartellieri; Susanne Michen; Ralf Wiedemuth; Nadja Müller; Dirk Lindemann; Michael Bachmann; Monika Füssel; Gabriele Schackert; Achim Temme
Journal: J Immunol Date: 2015-03-04 Impact factor: 5.422

3. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo.

Authors: Elke Pogge von Strandmann; Hinrich P Hansen; Katrin S Reiners; Roland Schnell; Peter Borchmann; Sabine Merkert; Venkateswara R Simhadri; Andreas Draube; Marcel Reiser; Ingvill Purr; Michael Hallek; Andreas Engert
Journal: Blood Date: 2005-10-06 Impact factor: 22.113

4. Natural killer cell activity and head and neck cancer: a clinical assessment.

Authors: S P Schantz; E J Shillitoe; B Brown; B Campbell
Journal: J Natl Cancer Inst Date: 1986-10 Impact factor: 13.506

Review 5. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations.

Authors: Kerry S Campbell; Amanda K Purdy
Journal: Immunology Date: 2011-01-07 Impact factor: 7.397

6. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction.

Authors: Elisabetta Contardi; Giulio L Palmisano; Pier Luigi Tazzari; Alberto M Martelli; Federica Falà; Marina Fabbi; Tomohiro Kato; Enrico Lucarelli; Davide Donati; Letizia Polito; Andrea Bolognesi; Francesca Ricci; Sandra Salvi; Vittoria Gargaglione; Stefano Mantero; Marco Alberghini; Giovanni Battista Ferrara; Maria Pia Pistillo
Journal: Int J Cancer Date: 2005-11-20 Impact factor: 7.396

Review 7. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.

Authors: Mahiuddin Ahmed; Nai-Kong V Cheung
Journal: FEBS Lett Date: 2013-12-01 Impact factor: 4.124

8. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice.

Authors: E Gorelik; R H Wiltrout; K Okumura; S Habu; R B Herberman
Journal: Int J Cancer Date: 1982-07-15 Impact factor: 7.396

9. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Authors: Jedd D Wolchok; James P Allison; Dmitriy Zamarin; Rikke B Holmgaard; Sumit K Subudhi; Joon Seok Park; Mena Mansour; Peter Palese; Taha Merghoub
Journal: Sci Transl Med Date: 2014-03-05 Impact factor: 17.956

10. Accelerated tumor growth in mice deficient in DNAM-1 receptor.

Authors: Akiko Iguchi-Manaka; Hirayasu Kai; Yumi Yamashita; Kai Shibata; Satoko Tahara-Hanaoka; Shin-ichiro Honda; Teruhito Yasui; Hitoshi Kikutani; Kazuko Shibuya; Akira Shibuya
Journal: J Exp Med Date: 2008-11-24 Impact factor: 14.307

379 in total

1. Adoptive Transfer of NKG2D CAR mRNA-Engineered Natural Killer Cells in Colorectal Cancer Patients.

Authors: Lin Xiao; Dongzhi Cen; Haining Gan; Yan Sun; Nanqi Huang; Hanzhen Xiong; Qiongmei Jin; Liqun Su; Xuejuan Liu; Kejian Wang; Guangrong Yan; Tianfa Dong; Shangbiao Wu; Pengzhi Zhou; Jinshan Zhang; Weixiang Liang; Junlan Ren; Yaoshu Teng; Can Chen; Xue Hu Xu
Journal: Mol Ther Date: 2019-03-20 Impact factor: 11.454

2. Patrolling Monocytes Control NK Cell Expression of Activating and Stimulatory Receptors to Curtail Lung Metastases.

Authors: Prakash Babu Narasimhan; Tobias Eggert; Yanfang Peipei Zhu; Paola Marcovecchio; Melissa A Meyer; Runpei Wu; Catherine C Hedrick
Journal: J Immunol Date: 2019-11-25 Impact factor: 5.422

3. Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds.

Authors: Flavia Fontana; Raquél Bartolo; Hélder A Santos
Journal: Adv Exp Med Biol Date: 2021 Impact factor: 2.622

Review 4. TGFβ biology in cancer progression and immunotherapy.

Authors: Rik Derynck; Shannon J Turley; Rosemary J Akhurst
Journal: Nat Rev Clin Oncol Date: 2020-07-24 Impact factor: 66.675

5. Bench-to-bedside translation of interleukin-15 for immunotherapy: principles and challenges.

Authors: Chalet Tan; Thomas A Waldmann
Journal: Expert Opin Drug Deliv Date: 2020-05-19 Impact factor: 6.648

6. Grainyhead-like-2 confers NK-sensitivity through interactions with epigenetic modifiers.

Authors: Ian MacFawn; Hannah Wilson; Luke A Selth; Ian Leighton; Ilya Serebriiskii; R Christopher Bleackley; Osama Elzamzamy; Joshua Farris; Phillip M Pifer; Jennifer Richer; Steven M Frisch
Journal: Mol Immunol Date: 2018-11-30 Impact factor: 4.407

7. Dendritic Cell-Derived IL-32α: A Novel Inhibitory Cytokine of NK Cell Function.

Authors: Laurent Gorvel; Daniel Korenfeld; Thomas Tung; Eynav Klechevsky
Journal: J Immunol Date: 2017-07-12 Impact factor: 5.422

8. Uncovering the underlying mechanism of cancer tumorigenesis and development under an immune microenvironment from global quantification of the landscape.

Authors: Li Wenbo; Jin Wang
Journal: J R Soc Interface Date: 2017-06 Impact factor: 4.118

9. Blocking LLT1 (CLEC2D, OCIL)-NKRP1A (CD161) interaction enhances natural killer cell-mediated lysis of triple-negative breast cancer cells.

Authors: Armando M Marrufo; Stephen O Mathew; Pankaj Chaudhary; Joseph D Malaer; Jamboor K Vishwanatha; Porunelloor A Mathew
Journal: Am J Cancer Res Date: 2018-06-01 Impact factor: 6.166

10. In vivo Anti-Cancer Effects of Resveratrol Mediated by NK Cell Activation.

Authors: Yoojin Lee; Heewook Shin; Jongsun Kim
Journal: J Innate Immun Date: 2020-09-16 Impact factor: 7.349